IP Verse

Sandoz Inc. vs Acerta Pharma B.V. et al.

The detailed information for PTAB case with proceeding number IPR2023-00478 filed by Sandoz Inc. against Acerta Pharma B.V. et al. on Feb 3, 2023. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: IPR2023-00478
Filing Date: Feb 3, 2023
Petitioner: Sandoz Inc.
Respondent: Acerta Pharma B.V. et al.
Status: Institution Denied
Respondent Application Number: 15112968
Respondent Tech Center: 1600
Respondent Patent Number: 10272083
Institution Decision Date: Aug 7, 2023
Termination Date: Aug 7, 2023

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
Denying Institution of Inter Partes Review 35 U.S.C. 314	Aug 7, 2023	PAPER	BOARD
Petitioner’s Authorized Response In Opposition To Patent Owner’s Motion For Leave To File Request For Certificate Of Correction	Jun 8, 2023	PAPER	PETITIONER
Petitioner's Updated Exhibit List (as of 08-08-2023)	Jun 8, 2023	PAPER	PETITIONER
Ex. 1046 - COMPLAINT Acerta Pharma B.V. et al. Case No. 1:22-cv-00164-GBW, Dkt. 1 (D. Del. Feb. 4, 2022)v. Sandoz Inc.,	Jun 8, 2023	EXHIBIT	PETITIONER
Patent Owner's Authorized Sur-Reply	Jun 2, 2023	PAPER	PATENT OWNER
Petitioner's Authorized Reply to POPR	May 26, 2023	PAPER	PETITIONER
Patent Owner's Motion for Leave	May 24, 2023	PAPER	PATENT OWNER
EX2010 - Merck Bloomberg Report	May 24, 2023	EXHIBIT	PATENT OWNER
Patent Owner's Amended Exhibit List	May 24, 2023	PAPER	PATENT OWNER
Exhibit 3003	May 23, 2023	EXHIBIT	BOARD
Exhibit 3002	May 15, 2023	EXHIBIT	BOARD
EX2001 - Defendants' Invalidity Contentions	May 15, 2023	EXHIBIT	PATENT OWNER
EX2004 - Merck-Covalution Agreement	May 15, 2023	EXHIBIT	PATENT OWNER
EX2005 - Claim Construction Stipulation, Acerta Pharma, et al. v. Alembic Pharmaceuticals Ltd, et al., No. 22-154-GBW-SRF, Dkt No 1083 (D. Del. Mar. 13, 2023)	May 15, 2023	EXHIBIT	PATENT OWNER
EX2006 - 108th Congress, House Report H.R. 2391	May 15, 2023	EXHIBIT	PATENT OWNER
EX2007 - S7520, Senate Report, June 25, 2004	May 15, 2023	EXHIBIT	PATENT OWNER
EX2008 - Acerta Company Report	May 15, 2023	EXHIBIT	PATENT OWNER
EX2009 - Acerta History Report	May 15, 2023	EXHIBIT	PATENT OWNER
Patent Owner's Motion To Seal	May 15, 2023	PAPER	PATENT OWNER
Patent Owner's Preliminary Response	May 15, 2023	PAPER	PATENT OWNER
Order: Granting Petitioners Motion for Admission Pro Hac Vice of Charles B. Klein and Eimeric Reig-Plessis	May 10, 2023	PAPER	BOARD
Exhibit 3001	May 9, 2023	EXHIBIT	BOARD
Petitioner’s Unopposed Motion For Pro Hac Vice Admission Of Charles B. Klein And Eimeric Reig-Plessis	May 3, 2023	PAPER	PETITIONER
Ex. 1044 - Declaration Of Charles B. Klein In Support Of Motion For PHV Admission	May 3, 2023	EXHIBIT	PETITIONER
Ex. 1045 - Declaration Of Eimeric Reig-Plessis In Support Of Motion For PHV Admission	May 3, 2023	EXHIBIT	PETITIONER
EXPUNGED	May 3, 2023	PAPER	PETITIONER
Notice : Mandatory Notices by Patent Owner	Feb 23, 2023	PAPER	PATENT OWNER
Notice : Power of Attorney for Patent Owner	Feb 23, 2023	PAPER	PATENT OWNER
Notice: Notice filing date accorded	Feb 15, 2023	PAPER	BOARD
Ex. 1001- U.S. Patent No. 10,272,083 to Hamdy et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1005 - U.S. Patent No. 9,758,524 to Barf, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1006 - PCT International Publication No. WO2013/010868 to Barf, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1007 - U.S. Provisional Application No. 61/509,397 to Barf, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1008 - Bruce D. Cheson, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1009 - Ranjana H. Advani, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1010 - John C. Byrd, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1011 - U.S. Provisional Application No. 61/929,742	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1012 - U.S. Provisional Application No. 61/974,665	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1013 - U.S. Provisional Application No. 62/035,777	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1014 - Stefano A. Pileri, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1015 - M. Dreyling, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1016 - IMBRUVICA™ (ibrutinib) Prescribing Information	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1017 U.S. Food and Drug Administration Office of Clinical Pharmacology	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1018 - Akintunde Akinleye, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1019 - Claire V. Hutchinson, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1020 - Jennifer R. Brown, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1021 - Daniel W. Pierce, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1022 - Simon Rule, et al.,	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1024 - U.S. Food and Drug Administration- Good Review Practice	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1025 - U.S. Patent No. 7,732,454	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1026 - International Conference on Harmonisation	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1027 - U.S. Food and Drug Administration, Guidance for Industry	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1028 - U.S. Food and Drug Administration, Guidance for Industry (MSSD)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1029 - Erica K. Evans, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1030 - Tjeerd Barf, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1031 - Amit Mahipal, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1032 - Sarah Brumskill, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1033 - Toshio Yoshizawa, et al.,	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1035 - CALQUENCE® (acalabrutinib) Prescribing Information	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1036 - Jan de Jong, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1037 - Dominique Levêque	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1038 - ZYDELIG® (idelalisib) Prescribing Information	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1039 - TASIGNA® (nilotinib) Prescribing Information	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1040 - JAKAFI™ (ruxolitinib) Prescribing Information	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1041 - LYNPARZA™ (olaparib) Prescribing Information	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1042 - Betty Y. Chang, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1043 - Yan Bao, et al.	Feb 3, 2023	EXHIBIT	PETITIONER
Notice : Executed Power of Attorney - Sandoz, Inc.	Feb 3, 2023	PAPER	PETITIONER
Ex. 1004 - Prosecution History of U.S. Patent No. 10,272,083 (Part 1)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1004 - Prosecution History of U.S. Patent No. 10,272,083 (Part 2)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1004 - Prosecution History of U.S. Patent No. 10,272,083 (Part 3)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1004 - Prosecution History of U.S. Patent No. 10,272,083 (Part 4)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1004 - Prosecution History of U.S. Patent No. 10,272,083 (Part 5)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1004 - Prosecution History of U.S. Patent No. 10,272,083 (Part 6)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1023 - Prosecution History of U.S. Patent No. 9,758,524 (Part 1)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1023 - Prosecution History of U.S. Patent No. 9,758,524 (Part 2)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1023 - Prosecution History of U.S. Patent No. 9,758,524 (Part 3)	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1034 - Plaintiffs’ Initial Infringement Contentions to Def Sandoz Inc.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1003 -Declaration Of Sylvia D. Hall-Ellis, Ph.D.	Feb 3, 2023	EXHIBIT	PETITIONER
Ex. 1002 - Declaration Of John P. Fruehauf, M.D., Ph.D.	Feb 3, 2023	EXHIBIT	PETITIONER
Petition : as filed	Feb 3, 2023	PAPER	PETITIONER